Lasa Supergenics: Annual Secretarial Compliance Report Highlights Non-Compliance
Lasa Supergenics Limited's Annual Secretarial Compliance Report for FY26 reveals multiple SEBI regulation breaches. Fines were levied for delayed appointment of a Compliance Officer and late submissions of Shareholding Pattern, shareholder complaints, and Corporate Governance Report for Q4 FY26. The company has since made these filings.
While the report highlights non-compliance, these appear to be procedural delays rather than fundamental business issues. The company has taken corrective actions by filing the required documents. The impact is medium as it points to internal control weaknesses but has been addressed.
The announcement details several instances of non-compliance with SEBI regulations, including delayed filings and appointments, which have resulted in fines. This indicates a negative operational and compliance performance.
Lasa Supergenics Limited has submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report, dated May 29, 2025, highlights several instances of non-compliance with SEBI regulations. Key issues include a delay in appointing a qualified Company Secretary as Compliance Officer for the quarter ended December 31, 2025, leading to a fine of ₹20,060 from both BSE and NSE. Additionally, the company failed to submit the Shareholding Pattern for the quarter ended March 31, 2026, within the stipulated 21 days, incurring fines of ₹49,560 each from BSE and NSE. Similar delays were reported for the statement on shareholder complaints and the Quarterly Corporate Governance Report for the same quarter, also resulting in fines. The Reconciliation of Share Capital Audit Report for the quarter ended March 31, 2026, was also not submitted within the prescribed 30 days. The report attributes these delays to the late receipt of quarterly reports due to delayed bill payments by the company. The company has since filed the Shareholding Pattern, shareholder complaints statement, and Corporate Governance Report on May 12, 2026. The report also notes past non-compliances related to board composition, disclosure of related party transactions, and insider trading, for which remedial actions and fine payments have been made.
What to do with a filing like this
Lasa Supergenerics Limited filed this with the NSE as a statutory disclosure, categorised under secretarial compliance report. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lasa Supergenerics Limited. Read the original for the full detail.